

Full Portfolio Holdings* as of May 31, 2022

The value of holdings represents the market value for non-derivative positions and unrealized appreciation/(depreciation) for derivative positions.

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
BASE CURRENCY					
US DOLLAR			2,136,346	2,136,346	0.16%
COMMON STOCKS					
UnitedHealth Group, Inc.			269,607	133,935,366	9.83%
Eli Lilly & Co.			332,285	104,151,410	7.65%
Pfizer, Inc.			1,933,536	102,554,749	7.53%
Bristol-Myers Squibb Co.			838,872	63,292,892	4.65%
Danaher Corp.			217,330	57,336,001	4.21%
Humana, Inc.			110,811	50,333,681	3.70%
Zoetis, Inc.			253,955	43,408,528	3.19%
Boston Scientific Corp.			960,665	39,396,872	2.89%
Becton Dickinson and Co.			136,747	34,979,883	2.57%
Stryker Corp.			143,790	33,718,755	2.48%
Edwards Lifesciences Corp.			330,486	33,329,513	2.45%
Centene Corp.			346,456	28,215,377	2.07%
Agilent Technologies, Inc.			197,174	25,151,515	1.85%
Vertex Pharmaceuticals, Inc.			83,935	22,549,138	1.66%
HCA Healthcare, Inc.			106,287	22,362,785	1.64%
Syneos Health, Inc.			289,035	21,356,796	1.57%
Baxter International, Inc.			250,825	19,075,241	1.40%
Molina Healthcare, Inc.			62,533	18,148,327	1.33%
AstraZeneca plc			268,685	17,862,179	1.31%
Daiichi Sankyo Co., Ltd.			661,525	17,543,663	1.29%
Novartis AG			192,340	17,472,124	1.28%
DexCom, Inc.			48,330	14,399,440	1.06%
Teleflex, Inc.			48,784	14,037,108	1.03%
Laboratory Corp. of America Holdings			56,229	13,872,819	1.02%
UCB S.A.			155,870	13,751,962	1.01%
Illumina, Inc.			55,618	13,319,399	0.98%
Insulet Corp.			59,375	12,675,375	0.93%
Hologic, Inc.			167,013	12,571,069	0.92%
Encompass Health Corp.			181,693	11,908,159	0.87%
Chugai Pharmaceutical Co., Ltd.			428,400	11,711,666	0.86%
Waters Corp.			34,552	11,331,328	0.83%
Align Technology, Inc.			38,500	10,689,140	0.78%
Alkermes plc			318,759	9,514,956	0.70%
Regeneron Pharmaceuticals, Inc.			14,302	9,507,111	0.70%
Covetrus, Inc.			445,109	9,267,169	0.68%
Smith & Nephew plc			554,172	9,040,532	0.66%
Intra-Cellular Therapies, Inc.			154,974	8,895,508	0.65%
Exact Sciences Corp.			175,492	8,741,257	0.64%
Seagen, Inc.			60,021	8,143,649	0.60%
Koninklijke Philips N.V.			303,954	7,834,912	0.58%

Full Portfolio Holdings* as of May 31, 2022

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
DiaSorin S.p.A.			58,907	7,754,429	0.57%
ConvaTec Group plc			2,735,083	7,444,911	0.55%
Hypera S.A.			888,600	7,252,695	0.53%
Moderna, Inc.			49,555	7,201,828	0.53%
Owens & Minor, Inc.			202,892	7,076,873	0.52%
Kyowa Kirin Co., Ltd.			326,700	7,038,504	0.52%
Inari Medical, Inc.			105,498	6,941,768	0.51%
Ono Pharmaceutical Co., Ltd.			258,245	6,837,499	0.50%
Genus plc			195,652	6,804,532	0.50%
Bio-Techne Corp.			18,302	6,766,798	0.50%
Abcam plc			448,088	6,671,878	0.49%
Ironwood Pharmaceuticals, Inc.			590,129	6,650,754	0.49%
Horizon Therapeutics plc			73,919	6,629,795	0.49%
Glaukos Corp.			155,172	6,335,673	0.47%
Genmab A/S			20,750	6,315,451	0.46%
agilon health, Inc.			321,178	6,134,500	0.45%
Hikma Pharmaceuticals plc			281,994	6,032,508	0.44%
Eisai Co., Ltd.			145,795	6,004,101	0.44%
NanoString Technologies, Inc.			365,049	5,709,366	0.42%
Amedisys, Inc.			49,005	5,680,170	0.42%
WuXi AppTec Co., Ltd.			440,915	5,449,307	0.40%
Ascendis Pharma A/S			59,723	5,047,191	0.37%
Tecan Group AG			14,412	4,676,044	0.34%
QuidelOrtho Corp.			49,084	4,664,453	0.34%
Hapvida Participacoes e Investimentos S.A.			2,876,316	4,067,047	0.30%
Elanco Animal Health, Inc.			167,597	3,972,049	0.29%
Veracyte, Inc.			214,905	3,778,030	0.28%
Karuna Therapeutics, Inc.			35,674	3,721,512	0.27%
Argenx SE			11,898	3,680,051	0.27%
Alnylam Pharmaceuticals, Inc.			26,327	3,311,937	0.24%
Apellis Pharmaceuticals, Inc.			79,409	3,291,503	0.24%
AdaptHealth Corp.			179,518	3,229,529	0.24%
Sage Therapeutics, Inc.			101,082	3,160,834	0.23%
Everest Medicines Ltd.			1,072,300	3,013,788	0.22%
PTC Therapeutics, Inc.			100,968	2,965,430	0.22%
Sarepta Therapeutics, Inc.			40,629	2,958,604	0.22%
Astellas Pharma, Inc.			183,000	2,922,677	0.21%
Zentalis Pharmaceuticals, Inc.			120,433	2,903,640	0.21%
Ultragenyx Pharmaceutical, Inc.			61,382	2,878,816	0.21%
Blueprint Medicines Corp.			48,442	2,664,310	0.20%
CSPC Pharmaceutical Group Ltd.			2,386,000	2,549,381	0.19%
Myovant Sciences Ltd.			216,972	2,250,000	0.17%
NeoGenomics, Inc.			259,841	2,187,861	0.16%
Cano Health, Inc.			423,852	2,182,838	0.16%
Amicus Therapeutics, Inc.			284,659	2,169,102	0.16%

Full Portfolio Holdings* as of May 31, 2022

Security	Coupon	Maturity	Shares/Par	Value	% of Net Assets
Aclaris Therapeutics, Inc.			167,189	2,138,347	0.16%
Celldex Therapeutics, Inc.			88,676	2,085,660	0.15%
Merus N.V.			110,055	2,042,621	0.15%
Venus MedTech Hangzhou, Inc.			1,089,000	1,876,992	0.14%
Arvinas, Inc.			43,155	1,799,132	0.13%
Revolution Medicines, Inc.			99,657	1,692,176	0.12%
ImmunoGen, Inc.			424,576	1,553,948	0.11%
Mirati Therapeutics, Inc.			36,557	1,431,572	0.11%
Orion Acquisition Corp.			110,246	1,078,206	0.08%
Kymera Therapeutics, Inc.			66,837	953,764	0.07%
InnoCare Pharma Ltd.			688,700	925,784	0.07%
Stevanato Group S.p.A.			41,756	674,359	0.05%
Relay Therapeutics, Inc.			24,141	393,015	0.03%
SHORT-TERM INVESTMENTS					
Fixed Income Clearing Corp.		6/1/2022	9,099,853	9,099,853	0.67%
DERIVATIVES - FOREIGN CURRENCY					
BRAZILIAN REAL			1,906,284	84	0.00%
SWISS FRANC			12	0	0.00%
JAPANESE YEN			1	0.00	0.00%
POUND STERLING			(0.01)	0.00	0.00%
HONG KONG DOLLAR			37	0	0.00%
DERIVATIVES - FOREIGN CURRENCY EXCHANGE CONTRACTS (SPOT)					
JAPANESE YEN		6/1/2022	93,142,962	(8,156)	0.00%
TOTAL INVESTMENTS				1,364,241,024	100.15%
OTHER ASSETS LESS LIABILITIES				(2,032,236)	-0.15%
TOTAL NET ASSETS				1,362,208,788	100.00%

* This unaudited information is being presented pursuant to the Fund's Policy on Disclosure of Portfolio Holdings. Please see the Fund's Statement of Additional Information on www.hartfordfunds.com for a discussion of the Fund's policy. Holdings are provided for informational purposes only and should not be construed as a recommendation or investment advice. Portfolio holdings are as of the date noted and are subject to change at any time. Holdings may not be representative of current or future investments.

Unlike the Fund's regulatory filings, the portfolio data and its presentation in this document is not required to conform to Generally Accepted Accounting Principles (GAAP) and Securities and Exchange Commission (SEC) presentation requirements. Therefore, it may differ from that provided in the complete portfolio of investments in the annual and semiannual report to shareholders filed with the SEC on Form N-CSR, and the complete portfolio of investments filed in the first and third quarter on Form N-PORT.

Investing involves risk, including the possible loss of principal. Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in the fund's prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC, Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC, an SEC registered investment adviser.

227833 03/22